Focus Series: Alternative Sampling StrategiesAlternative Sampling Devices to Collect Dried Blood Microsamples: State-of-the-ArtDelahaye, Lisa PharmD*; Veenhof, Herman PhD†; Koch, Birgit C. P. PhD‡; Alffenaar, Jan-Willem C. PhD§,¶,‖; Linden, Rafael PhD**; Stove, Christophe PhD*Author Information * Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Belgium; †University of Groningen, Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands; ‡Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; §Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; ¶Department of Pharmacy, Westmead Hospital, Westmead, NSW, Australia; ‖Marie Bashir Institute of Infectious Diseases and Biosecurity, The University of Sydney, Camperdown, NSW, Australia; and **Laboratory of Analytical Toxicology, Institute of Health Sciences, Universidade Feevale, Novo Hamburgo, RS, Brazil. Correspondence: Christophe Stove, PhD, Ottergemsesteenweg 460, 9000 Ghent, Belgium (e-mail: [email protected]). This research was supported by the FWO Research Foundation-Flanders (G0E0916N). The authors declare no conflict of interest. Therapeutic Drug Monitoring: June 2021 - Volume 43 - Issue 3 - p 310-321 doi: 10.1097/FTD.0000000000000864 Buy Metrics Abstract Dried blood spots (DBS) have been used in newborn screening programs for several years. More recently, there has been growing interest in using DBS as a home sampling tool for the quantitative determination of analytes. However, this presents challenges, mainly because of the well-known hematocrit effect and other DBS-specific parameters, including spotted volume and punch site, which could add to the method uncertainty. Therefore, new microsampling devices that quantitatively collect capillary dried blood are continuously being developed. In this review, we provided an overview of devices that are commercially available or under development that allow the quantitative (volumetric) collection of dried blood (-based) microsamples and are meant to be used for home or remote sampling. Considering the field of therapeutic drug monitoring (TDM), we examined different aspects that are important for a device to be implemented in clinical practice, including ease of patient use, technical performance, and ease of integration in the workflow of a clinical laboratory. Costs related to microsampling devices are briefly discussed, because this additionally plays an important role in the decision-making process. Although the added value of home sampling for TDM and the willingness of patients to perform home sampling have been demonstrated in some studies, real clinical implementation is progressing at a slower pace. More extensive evaluation of these newly developed devices, not only analytically but also clinically, is needed to demonstrate their real-life applicability, which is a prerequisite for their use in the field of TDM. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.